Initial Public Offering
Baird served as a co- manager on this offering.
AboutNatera, Inc. (“Natera” or the “Company”) (NASDAQ: NTRA) recently completed an initial public offering of 10,900,000 shares of its common stock at a price of $18.00 per share, generating gross proceeds of $196.2 million. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including continued investments in research and development for the Company’s core technology and development of its product offerings as well as acquisitions of complementary businesses, technologies or other assets.
Natera is a rapidly growing diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease worldwide. The Company’s novel molecular assays reliably measure many informative regions across the genome from samples as small as a single cell. Natera has launched seven molecular diagnostic tests since 2009, and intends to launch new products in prenatal testing and oncology in the future. In March 2013, Natera launched Panorama, its non-invasive prenatal test, or NIPT, for detecting fetal chromosomal abnormalities. Based on extensive data published in the journals Obstetrics & Gynecology, the American Journal of Obstetrics & Gynecology and Prenatal Diagnosis, Natera believes Panorama is the most accurate NIPT commercially available in the United States. Natera is headquartered in San Carlos, California.
For additional information about this transaction, please contact:
- July 2015
- Natera, Inc.
- Target Location
- North America